Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Postoperative Period × Endocrine × Clear all
NCT01709292 2026-04-16

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
24 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡